Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 1, 2006, Pages 39-43

  Inan, Saadet ^a   Cowan, Alan ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholestasis; Ethynylestradiol; Itch; Kappa opioid receptor; Nalfurafine; Nitric oxide; Rat

Indexed keywords

DYNORPHIN A; ETHINYLESTRADIOL; NALFURAFINE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTASIS; CLINICAL FEATURE; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RAT; RECEPTOR BINDING; SCRATCHING;

ANIMALS; BEHAVIOR, ANIMAL; CHOLESTASIS; ETHINYL ESTRADIOL; INJECTIONS, SUBCUTANEOUS; MALE; MORPHINANS; PRURITUS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SPIRO COMPOUNDS;

ANIMALIA;

EID: 33751074425     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.07.004     Document Type: Article

References (25)

1. Amarante L., and Duarte I.D. The κ-opioid agonist (±) bremazocine elicits peripheral antinociception by activation of the l-arginine/nitric oxide/cyclic GMP pathway. Eur J Pharmacol 454 (2002) 19-23
2. Andoh T., and Kuraishi Y. Nitric oxide enhances substance P-induced itch-associated responses in mice. Br J Pharmacol 138 (2003) 202-208
3. Benamar K., Geller E.B., and Adler M.W. Central or peripheral nitric oxide is required for the production of hypothermia induced by U50,488H. J Pharmacol Exp Ther 303 (2002) 375-378
4. Bergasa N.V., and Jones E.A. The pruritus of cholestasis. Semin Liver Dis 13 (1993) 319-327
5. Bergasa N.V., Sabol S.L., Young W.S., Kleiner D.E., and Jones E.A. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 268 (1995) G346-G354
6. Bergasa N.V. Pruritus in chronic liver disease: mechanisms and treatment. Curr Gastroenterol Rep 6 (2004) 10-16
7. Bergasa N.V. The pruritus of cholestasis. J Hepatology 43 (2005) 1078-1088
8. Bossard R., Stieger B., O'Neill B., Fricker G., and Meier P.J. Ethynylestradiol treatment induces multiple canalicular membrane transport alterations in rat liver. J Clin Invest 91 (1993) 2714-2720
9. Dimoulios P., Kolios G., Notas G., Matrella E., Xidakis C., Koulentaki M., et al. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis. Aliment Pharmacol Ther 21 (2005) 227-234
10. Elferink R.O. Cholestasis. Gut 52 Suppl II (2003) ii42-ii48
11. Fiorucci S., Clerici C., Antonelli E., Orlandi S., Goodwin B., Sadeghpour B.M., et al. Protective effects of 6-ethylchenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 313 (2005) 604-612
12. Inan S., and Cowan A. Kappa opioid agonists suppress choloroquine-induced scratching in mice. Eur J Pharmacol 502 (2004) 233-237
13. Inan S., and Cowan A. Reduced kappa-opioid activity in a rat model of cholestasis. Eur J Pharmacol 518 (2005) 182-186
14. Inan S., and Cowan A. Agmatine-induced stereotyped scratching in mice is antagonized by nalfurafine, a kappa opioid agonist. Pharmacologist 48 (2006) 38
15. Ma Z., and Wang X. The changes of serum nitric oxide level in patients with intrahepatic cholestasis of pregnancy. Zhonghua Fu Chan Ke Za Zhi 33 (1998) 148-149
16. Nagase H., Hayakawa J., Kawamura K., Kawai K., Takezawa Y., Matsuura H., et al. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull 46 (1998) 366-369
17. Neuberger J. Liver transplantation for cholestatic liver disease. Curr Treat Options Gastroenterol 6 (2003) 113-121
18. Pozzi E.J.S., Crocenzi F.A., Pellegrino J.M., Catania V.A., Luquita M.G., Marcelo G.R., et al. Ursodeoxycholate reduces ethinylestradiol glucuronidation in the rat: role in prevention of estrogen-induced cholestasis. J Pharmacol Exp Ther 306 (2003) 279-286
19. Togashi Y., Umeuchi H., Okano K., Ando N., Yoshizawa Y., Honda T., et al. Antipruritic activity of the κ-opioid receptor agonist, TRK-820. Eur J Pharmacol 435 (2002) 259-264
20. Trauner M. When bile ducts say NO: the good, the bad, and the ugly. Gastroenterology 124 (2003) 847-851
21. Trauner M., Wagner M., Fickert P., and Zollner G. Molecular regulation of hepatobiliary transport systems. Clinical implications for understanding and treating cholestasis. J Clin Gastroenterol 39 Suppl II (2005) S111-S124
22. Twycross R., Greaves M., Handwerker H., Jones E.A., Libretto S.E., Szepietowski J.C., et al. Itch: scratching more than the surface. Q J Med 96 (2003) 7-26
23. Wakasa Y., Fujiwara A., Umeuchi H., Endoh T., Okano K., Tanaka T., et al. Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 75 (2004) 2947-2957
24. Wang Y., Tang K., Inan S., Siebert D., Holzgrabe U., Lee D.Y.W., et al. Comparison of pharmacological activities of three distinct κ ligands (salvinorin A, TRK-820 and 3FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312 (2005) 220-230
25. Wikström B., Gellert R., Ladefoged S.D., Danda Y., Akai M., Ide K., et al. κ-Opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16 (2005) 3742-3747